دورية أكاديمية
Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
| العنوان: | Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment |
|---|---|
| المؤلفون: | Brooks, D J, Agid, Y, Eggert, K, Widner, Håkan, Ostergaard, K, Holopainen, A |
| المصدر: | European Neurology; 53(4), pp 197-202 (2005) ; ISSN: 1421-9913 |
| بيانات النشر: | Karger |
| سنة النشر: | 2005 |
| المجموعة: | Lund University Publications (LUP) |
| مصطلحات موضوعية: | Neurology, wearing-off, catechol-O-methyltransferase inhibition, inhibitor, dopa-decarboxylase, levodopa, Parkinson's disease, Stalevo (R) |
| الوصف: | The aim of this study was to evaluate the efficacy of the new optimised levoclopa, Stalevo(R) (levoclopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-close wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCl) formulations along with adjunct entacapone (Comtess(R)/Comtan(R)). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCl to either an equivalent dose of Stalevo or levodopa/DDCl plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo, and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCl plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCl and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCl preparations. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://lup.lub.lu.se/record/229717Test; http://dx.doi.org/10.1159/000086479Test; pmid:15970632; wos:000231064500006; scopus:22744453722 |
| DOI: | 10.1159/000086479 |
| الإتاحة: | https://doi.org/10.1159/000086479Test https://lup.lub.lu.se/record/229717Test |
| رقم الانضمام: | edsbas.B271E880 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000086479 |
|---|